Foundation Medicine

Foundation Medicine, Inc. specializes in providing molecular information products that enhance cancer treatment by utilizing advanced genomic profiling techniques. The company's platform analyzes various cancer specimens to deliver personalized genomic insights, which assist physicians in optimizing treatment plans and support biopharmaceutical companies in developing targeted therapies and immunotherapies. Key clinical products include FoundationOne, which focuses on solid tumors, and FoundationOne Heme for blood-based cancers. Additionally, Foundation Medicine offers diagnostic assays such as Foundation Assay for Circulating Tumor and FoundationFocus CDxBRCA, aimed at identifying ovarian cancer in women. The company maintains collaborative agreements with major pharmaceutical firms and organizations, such as F. Hoffmann-La Roche Ltd. and the European Organisation for Research and Treatment of Cancer, to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine is a subsidiary of Roche Holdings, Inc.

Daniel Malarek

CEO

Aaron Dungca Needham

Senior Analyst Business Operations and Customer Experience

3 past transactions

Moffitt Cancer Center

Grant in 2023
Moffitt Cancer Center in Tampa, Florida, has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease.

Lexent Bio

Acquisition in 2020
Lexent Bio is focused on developing innovative liquid biopsy technology aimed at transforming cancer diagnosis and treatment. Based in San Francisco, California, the company specializes in providing clinically actionable information through its monitoring platform, which utilizes low-pass whole-genome sequencing and DNA methylation analysis. This technology enables oncologists to diagnose cancer, determine treatment options, and monitor patients' responses to therapy with greater speed and accuracy than traditional imaging methods. Established in 2014, Lexent Bio operates as a subsidiary of Foundation Medicine, Inc.

COTA Healthcare

Series B in 2016
COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.